Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:SAME'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.17 Med: 4.89 Max: 81.19
Current: 4.55
During the past 13 years, the highest Debt-to-EBITDA Ratio of PTrana Meditama Metropolitan Tbk was 81.19. The lowest was 0.17. And the median was 4.89.
ISX:SAME's Debt-to-EBITDA is ranked worse than 74.74% of 479
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs ISX:SAME: 4.55
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PTrana Meditama Metropolitan Tbk Debt-to-EBITDA Related Terms
PTrana Meditama Metropolitan Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:SAME vs HCA, THC, EHC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTrana Meditama Metropolitan Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PTrana Meditama Metropolitan Tbk (ISX:SAME) has a Debt-to-EBITDA of 4.66 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PTrana Meditama Metropolitan Tbk. This is near median its historical median of 4.89. Over the past decade, PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA has ranged from 0.17 to 81.19. According to the industry distribution chart, PTrana Meditama Metropolitan Tbk ranks #358 out of 479 companies in the Healthcare Providers & Services industry, placing it in the top 74.7%.
Is PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA too high?
PTrana Meditama Metropolitan Tbk's current Debt-to-EBITDA of 4.66 is near median its 10-year median of 4.89. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 81.19. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. PTrana Meditama Metropolitan Tbk's value of 4.66 is 112.8% above this industry median. Based on the distribution chart, PTrana Meditama Metropolitan Tbk ranks #358 out of 479 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PTrana Meditama Metropolitan Tbk has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PTrana Meditama Metropolitan Tbk's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PTrana Meditama Metropolitan Tbk ranks #358 out of 479 companies for Debt-to-EBITDA. This places PTrana Meditama Metropolitan Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. PTrana Meditama Metropolitan Tbk's value of 4.66 is 112.8% above this benchmark. Historically, PTrana Meditama Metropolitan Tbk's own Debt-to-EBITDA has ranged from 0.17 to 81.19 over the past decade. While the company's 10-year median is 4.89 vs. the industry median of 2.19, PTrana Meditama Metropolitan Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 479 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PTrana Meditama Metropolitan Tbk's current Debt-to-EBITDA of 4.66 is 112.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PTrana Meditama Metropolitan Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PTrana Meditama Metropolitan Tbk's current Debt-to-EBITDA is 4.66, which is near median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTrana Meditama Metropolitan Tbk stock overvalued right now?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk (ISX:SAME) is currently considered Fairly Valued. The stock's GF Value™ is Rp354.65, compared to a current price of Rp336.00 — trading 5.3% below its estimated fair value. The current Debt-to-EBITDA is 4.66, which is near median its 10-year median of 4.89 and 112.8% above the Healthcare Providers & Services industry median of 2.19. PTrana Meditama Metropolitan Tbk's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PTrana Meditama Metropolitan Tbk (ISX:SAME), the current Debt-to-EBITDA is 4.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTrana Meditama Metropolitan Tbk (ISX:SAME) Overvalued in 2026?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk stock appears to be undervalued.
The current stock price of Rp336.00 is trading 5.3% below its estimated GF Value™ of Rp354.65.
GuruFocus considers PTrana Meditama Metropolitan Tbk to be Fairly Valued.
Key valuation signals for ISX:SAME:
Debt-to-EBITDA: 4.66 (near median its 10-year median of 4.89)
GF Value™: Rp354.65 vs. price of Rp336.00 (5.3% below fair value)
Industry Position: 112.8% above the Healthcare Providers & Services median (#358 of 479)
No single metric tells the full story. See the ISX:SAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Sarana Meditama Metropolitan Tbk is engaged in managing hospitals. Its hospitals are operated under the brand name Omni Hospital. The company manages and evaluates its business based on its geographic location consisting of Omni Pulomas, Omni Alam Sutera, Omni Cikarang, OMNI Pekayon, and others. It operates in Banten, DKI Jakarta, and West Java.
64GF Score
Get the complete analysis for ISX:SAME
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SAME has been successfully added to your 
